Altimmune to Host Virtual R&D Day on March 13, 2025

Core Insights - Altimmune, Inc. is hosting a virtual R&D Day on March 13, 2025, featuring presentations from Key Opinion Leaders (KOLs) in obesity, MASH, and two additional indications for pemvidutide [1][2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapeutics, specifically pemvidutide, a GLP-1/glucagon dual receptor agonist targeting obesity, MASH, and other indications [4] Event Details - The R&D Day will cover the scientific rationale for pemvidutide, clinical data generated to date, and future development plans, including topline data from the Phase 2b trial in MASH expected in Q2 2025 [2]